📊 DAWN Key Takeaways
Investment Thesis
Day One Biopharmaceuticals is a pre-profitability biotech company with strong revenue growth (+20.6% YoY) but severely negative profitability metrics including -67.8% net margin and -$104.1M free cash flow. Despite solid liquidity (8.02x current ratio) and $197.1M cash, the company is burning cash rapidly and will need additional capital or significantly accelerated revenue growth to reach sustainability.
DAWN Strengths
- Strong revenue growth of 20.6% year-over-year demonstrates market traction and commercial progress
- Excellent liquidity position with 8.02x current ratio and $197.1M cash provides runway for operations
- Low leverage with 0.00x debt-to-equity ratio and minimal long-term debt reduces financial risk
- Significant stockholders' equity of $441.2M provides substantial cushion
DAWN Risks
- Severe operating losses of -$127.8M with -80.8% operating margin indicate core business is not profitable at scale
- Negative free cash flow of -$104.1M annually means cash runway is limited; at current burn rate, cash depletes within 1.9 years
- Net losses widening with -$107.3M net income suggests inability to control costs despite revenue growth
- Pre-profitability biotech model carries inherent R&D risk and requires sustained access to capital markets
Key Metrics to Watch
- Operating cash flow trend and path to operating profitability
- Revenue growth sustainability and gross margin expansion as product mix matures
- Cash burn rate and months of cash runway remaining
- Operating expense ratio relative to revenue and cost control improvements
DAWN Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 8.02x current ratio provides a solid financial cushion.
DAWN Profitability Ratios
DAWN vs Healthcare Sector
How Day One Biopharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
DAWN Balance Sheet & Liquidity
DAWN 5-Year Financial Trend
5-Year Trend Summary: Day One Biopharmaceuticals, Inc.'s revenue has grown significantly by 21% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.37 indicates the company is currently unprofitable.
DAWN Growth Metrics (YoY)
DAWN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $39.8M | -$4.4M | $-0.19 |
| Q2 2025 | $8.2M | -$4.4M | $-0.05 |
| Q1 2025 | N/A | -$36.0M | $-0.35 |
| Q3 2024 | N/A | -$4.4M | $-0.33 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DAWN Capital Allocation
DAWN SEC Filings
Access official SEC EDGAR filings for Day One Biopharmaceuticals, Inc. (CIK: 0001845337)
📋 Recent SEC Filings
❓ Frequently Asked Questions about DAWN
What is the AI rating for DAWN?
Day One Biopharmaceuticals, Inc. (DAWN) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are DAWN's key strengths?
Strong revenue growth of 20.6% year-over-year demonstrates market traction and commercial progress. Excellent liquidity position with 8.02x current ratio and $197.1M cash provides runway for operations.
What are the risks of investing in DAWN?
Severe operating losses of -$127.8M with -80.8% operating margin indicate core business is not profitable at scale. Negative free cash flow of -$104.1M annually means cash runway is limited; at current burn rate, cash depletes within 1.9 years.
What is DAWN's revenue and growth?
Day One Biopharmaceuticals, Inc. reported revenue of $158.2M.
Does DAWN pay dividends?
Day One Biopharmaceuticals, Inc. does not currently pay dividends.
Where can I find DAWN SEC filings?
Official SEC filings for Day One Biopharmaceuticals, Inc. (CIK: 0001845337) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DAWN's EPS?
Day One Biopharmaceuticals, Inc. has a diluted EPS of $-1.04.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.